U.S. Markets open in 2 hrs 7 mins
  • S&P Futures

    3,675.50
    +11.00 (+0.30%)
     
  • Dow Futures

    30,044.00
    +112.00 (+0.37%)
     
  • Nasdaq Futures

    12,504.00
    +41.75 (+0.34%)
     
  • Russell 2000 Futures

    1,858.00
    +10.80 (+0.58%)
     
  • Crude Oil

    46.18
    +0.54 (+1.18%)
     
  • Gold

    1,845.80
    +4.70 (+0.26%)
     
  • Silver

    24.39
    +0.25 (+1.03%)
     
  • EUR/USD

    1.2176
    +0.0027 (+0.2192%)
     
  • 10-Yr Bond

    0.9200
    0.0000 (0.00%)
     
  • Vix

    21.12
    -0.05 (-0.24%)
     
  • GBP/USD

    1.3482
    +0.0030 (+0.2211%)
     
  • USD/JPY

    103.9380
    +0.0780 (+0.0751%)
     
  • BTC-USD

    18,764.54
    -493.04 (-2.56%)
     
  • CMC Crypto 200

    368.08
    -6.33 (-1.69%)
     
  • FTSE 100

    6,546.13
    +55.86 (+0.86%)
     
  • Nikkei 225

    26,751.24
    -58.13 (-0.22%)
     

Recap: Ultragenyx Pharmaceutical Q3 Earnings

Benzinga Insights
·1 min read

Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) were flat in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share rose 42.35% over the past year to ($1.13), which beat the estimate of ($1.27).

Revenue of $81,470,000 up by 215.78% year over year, which beat the estimate of $53,890,000.

Looking Ahead

Ultragenyx Pharmaceutical hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Oct 27, 2020

View more earnings on RARE

Time: 05:00 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/yvtmu8mm

Recent Stock Performance

52-week high: $99.25

52-week low: $31.99

Price action over last quarter: Up 24.67%

Company Description

Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.